Home Newsletters Pancreatic Cell News Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed...

Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin

By
Justin.choi
-
0
Fractyl Health announced that the company has received approval from the FDA for an Investigational Device Exemption (IDE) to begin its Revitalize-2 pivotal study.
[Fractyl Health, Inc.]
6445212 BBBBBBBB items 1 apa 0 default asc 1 173674 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
Press Release

RELATED ARTICLES

Exit mobile version